Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD1a is a member of the CD1 family of transmembrane glycoproteins, which are structurally related to MHC Class I molecules but specialized in presenting lipid and glycolipid antigens to T-cells. It is highly expressed on cortical thymocytes and professional antigen-presenting cells, particularly Langerhans cells in the skin and dendritic cells in the thymus. In the thymus, CD1a plays a critical role in the selection and maturation of T-cells by presenting endogenous or exogenous lipid ligands. Clinically, CD1a is a primary diagnostic marker for Langerhans cell histiocytosis (LCH) and is expressed in certain T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL). Therapeutic strategies targeting CD1a involve monoclonal antibodies designed to deplete malignant cells or modulate lipid-mediated immune responses in inflammatory conditions.
Monoclonal antibodies targeting CD1a typically act via antibody-dependent cellular cytotoxicity (ADCC) or by blocking the presentation of lipid antigens to T-cells.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD1a antigen (CD1a).